Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response

Patients with neuroendocrine tumors (NETs) can be treated with peptide receptor radionuclide therapy (PRRT). Here, the somatostatin analogue octreotate radiolabeled with lutetium-177 is targeted to NET cells by binding to the somatostatin receptor subtype 2 (SST(2)). During radioactive decay, DNA da...

Descripción completa

Detalles Bibliográficos
Autores principales: Feijtel, Danny, Doeswijk, Gabriela N., Verkaik, Nicole S., Haeck, Joost C., Chicco, Daniela, Angotti, Carmelina, Konijnenberg, Mark W., de Jong, Marion, Nonnekens, Julie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738856/
https://www.ncbi.nlm.nih.gov/pubmed/33391488
http://dx.doi.org/10.7150/thno.51215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738856/
https://www.ncbi.nlm.nih.gov/pubmed/33391488
http://dx.doi.org/10.7150/thno.51215

Ejemplares similares